Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

• Gillessen S Department of Medical Oncology, Cantonal Hospital St. Gallen and University of Berne, Switzerland. Electronic address: silke.gillessen@kssg.ch.
• Attard G Department of Medical Oncology, The Institute of Cancer Research/Royal Marsden, London, UK.
• Beer TM Oregon Health & Science University Knight Cancer Institute, OR, USA.
• Beltran H Department of Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
• Bossi A Department of Radiation Oncology, Genito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France.
• Bristow R Department of Radiation Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, USA.
• Carver B Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, NY, USA.
• Castellano D Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
• Chung BH Department of Urology, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea.
• Clarke N Department of Urology, The Christie and Salford Royal Hospitals, Manchester, UK.
• Daugaard G Department of Medical Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
• Davis ID Monash University and Eastern Health, Eastern Health Clinical School, Box Hill, Australia.
• de Bono J Department of Medical Oncology, The Institute of Cancer Research/Royal Marsden, London, UK.
• Borges Dos Reis R Department of Urology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
• Drake CG Department of Medical Oncology, Division of Haematology/Oncology, Columbia University Medical Center, New York, NY, USA.
• Eeles R Department of Clinical Oncology and Genetics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
• Efstathiou E Department of Medical Oncology, University of Texas MD Anderson Cancer Center, TX, USA.
• Evans CP Department of Urology, University of California, Davis School of Medicine, CA, USA.
• Fanti S Department of Nuclear Medicine, Policlinico S. Orsola, Università di Bologna, Italy.
• Feng F Department of Radiation Oncology, University of California, San Francisco, CA, USA.
• Fizazi K Department of Medical Oncology, Gustave Roussy, University of Paris Sud, Paris, France.
• Frydenberg M Department of Surgery, Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University.
• Gleave M Department of Urology, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
• Halabi S Department of Clinical trials and Statistics, Duke University, Durham, NC, USA.
• Heidenreich A Department of Urology, University Hospital Köln, Köln, Germany.
• Higano CS Department of Medicine, Division of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, WA, USA.
• James N Department of Clinical Oncology, Clinical Oncology Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK.
• Kantoff P Department of Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
• Kellokumpu-Lehtinen PL Department of Clinical Oncology, Tampere University Hospital, Faculty of Medicine and Life Sciences, University of Tampere, Finland.
• Khauli RB Department of Urology, American University of Beirut Medical Center, Beirut, Lebanon.
• Kramer G Department of Urology, Medical University of Vienna, Vienna, Austria.
• Logothetis C Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA.
• Maluf F Department of Medical Oncology Hospital Israelita Albert Einstein and Department of Medical Oncology Beneficência Portuguesa de São Paulo.
• Morgans AK Department of Medical Oncology and Epidemiology, Vanderbilt University Medical Center, Division of Hematology/Oncology, Nashville, TN, USA.
• Morris MJ Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• Mottet N Department of Urology, University Hospital Nord St. Etienne, St. Etienne, France.
• Murthy V Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.
• Oh W Department of Medical Oncology, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
• Ost P Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
• Padhani AR Department of Radiology, Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
• Parker C Department of Clinical Oncology, Royal Marsden NHS Foundation Trust, Sutton, UK.
• Pritchard CC Department of Pathology, University of Washington, WA, USA.
• Roach M Department of Radiation Oncology, University of California, San Francisco, CA, USA.
• Rubin MA Department of Pathology, University of Bern and the Inselspital, Bern (CH).
• Ryan C Department of Medical Oncology, Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of, California, San Francisco, CA, USA.
• Saad F Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
• Sartor O Department of Medical Oncology, Tulane Cancer Center, New Orleans, LA, USA.
• Scher H Department of Medical Oncology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
• Sella A Department of Medical Oncology, Department of Oncology, Assaf Harofeh Medical Centre, Tel-Aviv University, Sackler School of Medicine, Zerifin, Israel.
• Shore N Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA.
• Smith M Department of Medical Oncology, Massachusetts General Hospital Cancer Centre, Boston, MA, USA.
• Soule H Prostate Cancer Foundation, Santa Monica, CA, USA.
• Sternberg CN Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
• Suzuki H Department of Urology, Toho University Sakura Medical Center, Japan.
• Sweeney C Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• Sydes MR MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
• Tannock I Department of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.
• Tombal B Department of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
• Valdagni R Department of Oncology and Haemato-oncology, Università degli Studi di Milano. Radiation Oncology 1, Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
• Wiegel T Department of Radiation Oncology, Klinik für Strahlentherapie und Radioonkologie des Universitätsklinikum Ulm, Albert-Einstein-Allee, Ulm, Germany.
• Omlin A Department of Medical Oncology, Cantonal Hospital St. Gallen and University of Berne, Switzerland.

Show more…

Advanced and high-risk localized prostate cancer

Castration-naive and castration-resistant prostate cancer

Consensus

Oligometastatic prostate cancer

Therapeutics

Humans

Male

Neoplasm Staging

Practice Guidelines as Topic

Prostatic Neoplasms